Clinical Trial Update: Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH [Phase 2]

View source ↗

Summary

Phase 2 trial of daratumumab with gemcitabine, dexamethasone, and cisplatin in relapsed/refractory CD38+ peripheral T-cell lymphoma subtypes (PTCL-NOS, AITL, TF…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioimmunoblastic T-cell Lymphoma
• Follicular Helper Cell Lymphoma
• Peripheral T-cell Lymphoma Not Otherwise Specified

Drugs mentioned

• Cisplatin (Platinol) (cisplatin)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (Darzalex) (daratumumab)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2025-03-28